Nickerson Joan 4
4 · Verve Therapeutics, Inc. · Filed Apr 3, 2024
Insider Transaction Report
Form 4
Nickerson Joan
Chief Administrative Officer
Transactions
- Exercise/Conversion
Common Stock
2024-04-01+3,315→ 10,173 total - Sale
Common Stock
2024-04-02$8.24/sh−1,514$12,475→ 8,659 total - Exercise/Conversion
Restricted Stock Units
2024-04-01−3,315→ 9,945 total→ Common Stock (3,315 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- [F2]Includes 1,364 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
- [F3]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 17, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F4]On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027.